ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 837.3 USD | +0.66% |
|
+2.73% | +43.64% |
| 08:15am | US FDA Staff Flags Potential Limited Benefit of Eli Lilly's Alzheimer's Disease Drug | MT |
| Jun. 06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.77% | 265 M€ | +4.29% | - | |
| 0.74% | 57 M€ | +23.05% | - | |
| 0.72% | 14 M€ | +16.19% | - | |
| 0.72% | 1,487 M€ | +8.44% | - | |
| 0.72% | 1 M€ | -.--% | ||
| 0.66% | 8 M€ | +5.48% | - | |
| 0.60% | 9 M€ | +10.29% | ||
| 0.58% | 727 M€ | +8.36% | ||
| 0.58% | 2,517 M€ | +13.94% | - | |
| 0.54% | 283 M€ | +21.58% | ||
| 0.50% | 15 M€ | -1.62% | - | |
| 0.48% | 0 M€ | 0.00% | - | |
| 0.47% | 571 M€ | +8.67% | - | |
| 0.46% | 7 M€ | +0.11% | - | |
| 0.43% | 391 M€ | +9.74% | - | |
| 0.43% | 25 M€ | +3.81% | - | |
| 0.42% | 9 M€ | +10.34% | - | |
| 0.42% | 34 M€ | +9.03% | - | |
| 0.36% | 4 M€ | -.--% | - | |
| 0.36% | 35 M€ | +10.04% | - | |
| 0.36% | 169 M€ | +0.25% | - | |
| 0.34% | 45 M€ | 0.00% | - | |
| 0.33% | 112 M€ | +4.86% | - | |
| 0.31% | 306 M€ | +6.86% | - | |
| 0.31% | 39 M€ | +6.61% | - | |
| 0.29% | 6 M€ | +3.89% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
853.8
USD
Spread / Average Target
+1.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.64% | 754B | |
| +40.32% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +12.16% | 217B | |
| -2.29% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B | |
| +1.16% | 124B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
